- call +1-201-465-4211
- email sales@mrinsights.biz
Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors.
Scope of the Report:
This report focuses on the Anticancer Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Simply put, there are chemotherapy drugs and biological agents. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of tumors; the invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry, and genetic engineering have accelerated the process of drug development; research and development of anti-tumor drugs have been Enter a new era.
At present, there are more than 80 kinds of anti-cancer drugs commonly used in clinical practice in the world, which can be roughly divided into the following 6 categories: cytotoxic drugs, hormone drugs, biological response modifiers, monoclonal antibody drugs, other drugs, and auxiliary drugs.
The worldwide market for Anticancer Drugs is expected to grow at a CAGR of roughly 8.0% over the next five years, will reach 141900 million US$ in 2023, from 89300 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
CELGENE CORPORATION
Novartis AG
Pfizer Inc
Amgen Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
Hormonal Drugs
Market Segment by Applications, can be divided into
Lung Cancer
Breast Cancer
Leukemia
Colorectal Cancer
There are 15 Chapters to deeply display the global Anticancer Drugs market.
Chapter 1, to describe Anticancer Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anticancer Drugs, with sales, revenue, and price of Anticancer Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anticancer Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anticancer Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anticancer Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Anticancer Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
1.2.2 Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
1.2.3 Hormonal Drugs
1.3 Market Analysis by Applications
1.3.1 Lung Cancer
1.3.2 Breast Cancer
1.3.3 Leukemia
1.3.4 Colorectal Cancer
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 F. Hoffmann-La Roche Ltd
2.1.1 Business Overview
2.1.2 Anticancer Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 F. Hoffmann-La Roche Ltd Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eli Lilly and Company
2.2.1 Business Overview
2.2.2 Anticancer Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Eli Lilly and Company Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 CELGENE CORPORATION
2.3.1 Business Overview
2.3.2 Anticancer Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 CELGENE CORPORATION Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis AG
2.4.1 Business Overview
2.4.2 Anticancer Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis AG Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer Inc
2.5.1 Business Overview
2.5.2 Anticancer Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Inc Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Amgen Inc
2.6.1 Business Overview
2.6.2 Anticancer Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Amgen Inc Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bayer AG
2.7.1 Business Overview
2.7.2 Anticancer Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bayer AG Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 AstraZeneca
2.8.1 Business Overview
2.8.2 Anticancer Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 AstraZeneca Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Takeda Pharmaceutical Company Limited
2.9.1 Business Overview
2.9.2 Anticancer Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Takeda Pharmaceutical Company Limited Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Merck & Co.
2.10.1 Business Overview
2.10.2 Anticancer Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Merck & Co. Anticancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anticancer Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Anticancer Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Anticancer Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Anticancer Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Anticancer Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Anticancer Drugs Market Analysis by Regions
4.1 Global Anticancer Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Anticancer Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Anticancer Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Anticancer Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Anticancer Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Anticancer Drugs Sales and Growth Rate (2013-2018)
4.5 South America Anticancer Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Anticancer Drugs Sales and Growth Rate (2013-2018)
5 North America Anticancer Drugs by Countries
5.1 North America Anticancer Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Anticancer Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Anticancer Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Anticancer Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Anticancer Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Anticancer Drugs Sales and Growth Rate (2013-2018)
6 Europe Anticancer Drugs by Countries
6.1 Europe Anticancer Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Anticancer Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Anticancer Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Anticancer Drugs Sales and Growth Rate (2013-2018)
6.3 UK Anticancer Drugs Sales and Growth Rate (2013-2018)
6.4 France Anticancer Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Anticancer Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Anticancer Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Anticancer Drugs by Countries
7.1 Asia-Pacific Anticancer Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Anticancer Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Anticancer Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Anticancer Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Anticancer Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Anticancer Drugs Sales and Growth Rate (2013-2018)
7.5 India Anticancer Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Anticancer Drugs Sales and Growth Rate (2013-2018)
8 South America Anticancer Drugs by Countries
8.1 South America Anticancer Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Anticancer Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Anticancer Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Anticancer Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Anticancer Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Anticancer Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Anticancer Drugs by Countries
9.1 Middle East and Africa Anticancer Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Anticancer Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Anticancer Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Anticancer Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Anticancer Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Anticancer Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Anticancer Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Anticancer Drugs Sales and Growth Rate (2013-2018)
10 Global Anticancer Drugs Market Segment by Type
10.1 Global Anticancer Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Anticancer Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Anticancer Drugs Revenue and Market Share by Type (2013-2018)
10.2 Cytotoxic Drugs (Alkylating Agents, and Antimetabolites) Sales Growth and Price
10.2.1 Global Cytotoxic Drugs (Alkylating Agents, and Antimetabolites) Sales Growth (2013-2018)
10.2.2 Global Cytotoxic Drugs (Alkylating Agents, and Antimetabolites) Price (2013-2018)
10.3 Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors) Sales Growth and Price
10.3.1 Global Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors) Sales Growth (2013-2018)
10.3.2 Global Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors) Price (2013-2018)
10.4 Hormonal Drugs Sales Growth and Price
10.4.1 Global Hormonal Drugs Sales Growth (2013-2018)
10.4.2 Global Hormonal Drugs Price (2013-2018)
11 Global Anticancer Drugs Market Segment by Application
11.1 Global Anticancer Drugs Sales Market Share by Application (2013-2018)
11.2 Lung Cancer Sales Growth (2013-2018)
11.3 Breast Cancer Sales Growth (2013-2018)
11.4 Leukemia Sales Growth (2013-2018)
11.5 Colorectal Cancer Sales Growth (2013-2018)
12 Anticancer Drugs Market Forecast (2018-2023)
12.1 Global Anticancer Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Anticancer Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Anticancer Drugs Market Forecast (2018-2023)
12.2.2 Europe Anticancer Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Anticancer Drugs Market Forecast (2018-2023)
12.2.4 South America Anticancer Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Anticancer Drugs Market Forecast (2018-2023)
12.3 Anticancer Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Anticancer Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Anticancer Drugs Market Share Forecast by Type (2018-2023)
12.4 Anticancer Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Anticancer Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Anticancer Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Anticancer Drugs Picture
Table Product Specifications of Anticancer Drugs
Figure Global Sales Market Share of Anticancer Drugs by Types in 2017
Table An
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
